Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma

Julich-Haertel, Henrike; Urban, Sabine; Krawczyk, Marcin; Willms, Arnulf; Jankowski, Krzysztof; Patkowski, Waldemar; Kruk, Beata; Krasnodębski, Maciej; Ligocka, Joanna; Schwab, Robert; Richardsen, I.; Schaaf, Sebastian; Klein, A.; Gehlert, Sebastian; Sänger, Hanna; Casper, Markus; Bañales, Jesús M.; Schuppan, Detlef; Milkiewicz, Piotr; Lammert, Frank; Krawczyk, Marek; Lukacs‐Kornek, Veronika; Kornek, Miroslaw

doi:10.1016/j.jhep.2017.02.024

Cited by 135 publications

(158 citation statements)

References 42 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…Additionally, other study reported that MPs profiling for distinct MPs populations that are associated with chronic liver diseases robustly discriminates between chronic HCV infection and non-alcoholic fatty liver disease [136] . Julich-Haertel et al [137] successfully differentiated HCC and cholangiocarcinoma (CCA) from chronic diseases without liver tumours base on MPs profile. AnnexinV+ EpCAM+ CD147+ taMPs were increased in HCC and CCA.…”

Section: Tumor-associated Circulating Microparticlesmentioning

confidence: 99%

“…AnnexinV+ EpCAM+ CD147+ taMPs were increased in HCC and CCA. Moreover, AnnexinV+ EpCAM+ ASGPR1+ taMPs allowed to differentiate between liver cancer (HCC or CCA) and cirrhosis from tumour-free individuals (sensitivity 75% and specificity 47%) [137] . AnnexinV+ EpCAM+ ASGPR1+ taMPs were increased in liver cancer and decreased after liver resection indicating the powerful diagnostic accuracy (P < 0.05) and these MPs were correlated "moderately" with liver tumos diameters (r = 0.56, P > 0.001).…”

Section: Tumor-associated Circulating Microparticlesmentioning

confidence: 99%

See 1 more Smart Citation

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second cause of cancer related death due to latent liver disease, late diagnosis and non-available therapeutic treatment. Liver biopsy is still the gold standard in order to know the molecular biology of the tumor, its behaviour and invasive characteristics. Conventional diagnosis methods for HCC detection include imaging and serological tests with low sensitivity and specificity. In this review, we focus on the potential utility of certain serum biomarkers and a new approach, "liquid biopsy", in the management of HCC patients.

show abstract

Section: Tumor-associated Circulating Microparticlesmentioning

confidence: 99%

Section: Tumor-associated Circulating Microparticlesmentioning

confidence: 99%

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Among patients who presented recurrence, 4 had liver cirrhosis (HCV-related in 2 cases, steatohepatitic in one case and alcohol-related in the remaining one), 2 were affected by nonalcoholic steatohepatitis, and 1 had healthy liver. In the eight patients who did not display recurrence, the median follow-up was 21 months (range [16][17][18][19][20][21][22][23][24][25][26]. The only significant difference found between subjects with and without recurrence was age displayed recurrence, compared to those who remained cancer-free during follow-up (p=0.02) ( Table 4 and Fig.…”

Section: Resultsmentioning

confidence: 99%

“…This is important, since it strengthens the concept that organ-and disease-specific MPs should be studied, when looking for biomarkers with diagnostic and prognostic value. A recent example has been provided by Julich-Haertel and coll., who have found that MPs positive for AnnexinV, EpCAM, and ASGPR1 may help distinguishing between subjects with liver cancer and subjects with cirrhosis but no detectable liver malignancy [20].…”

Section: Discussionmentioning

confidence: 99%

“…While once considered just inert remnants of cellular processes, MPs are now recognized as important players in many physiological and pathological conditions, due to the fact that they act as cargos for nucleic acids and proteins and have the ability to translate functionally important biological information between cells. In the last few years, increasing attention has been paid the possible use of circulating MPs as novel biomarkers of disease, also in the field of hepatology [18][19][20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HepPar1-Positive Circulating Microparticles are Increased in Subjects with Hepatocellular Carcinoma and Predict Early Recurrence after Liver Resection

Abbate

Marcantoni

Giuliante

et al. 2017

Preprint

View full text Add to dashboard Cite

Circulating microparticles (MPs) are novel potential biomarkers in cancer patients. Their role in hepatocellular carcinoma (HCC) is under intensive investigation. In this study we tested the hypothesis that MPs expressing the antigen HepPar1 are increased in the blood of subjects with HCC and may serve as markers of early recurrence after liver resection (LR). We studied fifteen patients affected by HCC undergoing LR and used flow cytometry to assess the number of circulating HepPar1+ MPs. Ten subjects without HCC (five with liver cirrhosis and 5 with healthy liver) were used as controls. After LR, HCC patients were followed-up for early recurrence, which occurred in seven cases. The number of circulating HepPar1+ MPs was significantly higher in subjects affected by HCC, compared to individuals without cancer (p<0.01). We also found that, among HCC patients, the number of circulating HepPar1+ MPs, measured before LR, was significantly higher in those who displayed early recurrence compared to those without recurrence (p=0.02). Of note, other types of circulating MPs, such as those derived from endothelial cells (CD144+) or those produced by the activated endothelium (CD144+/CD62+) were not associated with HCC, neither could predict HCC recurrence. HepPar1+ MPs deserve further investigation as novel biomarkers of disease and prognosis in HCC patients.

show abstract

Extracellular Vesicles and Exosomes

Szabó

Momen-Heravi

2020

The Liver

View full text Add to dashboard Cite

Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma

Cited by 135 publications

References 42 publications

Performance of different biomarkers for the management of hepatocellular carcinoma

Performance of different biomarkers for the management of hepatocellular carcinoma

HepPar1-Positive Circulating Microparticles are Increased in Subjects with Hepatocellular Carcinoma and Predict Early Recurrence after Liver Resection

Extracellular Vesicles and Exosomes

Contact Info

Product

Resources

About